These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18473736)

  • 1. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice.
    Mastini C; Becker PD; Iezzi M; Curcio C; Musiani P; Forni G; Cavallo F; Guzmán CA
    Curr Cancer Drug Targets; 2008 May; 8(3):230-42. PubMed ID: 18473736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
    Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
    J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
    Cappello P; Triebel F; Iezzi M; Caorsi C; Quaglino E; Lollini PL; Amici A; Di Carlo E; Musiani P; Giovarelli M; Forni G
    Cancer Res; 2003 May; 63(10):2518-25. PubMed ID: 12750275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.
    Cifaldi L; Quaglino E; Di Carlo E; Musiani P; Spadaro M; Lollini PL; Wolf S; Boggio K; Forni G; Cavallo F
    Cancer Res; 2001 Apr; 61(7):2809-12. PubMed ID: 11306448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
    Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
    Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.
    Boggio K; Nicoletti G; Di Carlo E; Cavallo F; Landuzzi L; Melani C; Giovarelli M; Rossi I; Nanni P; De Giovanni C; Bouchard P; Wolf S; Modesti A; Musiani P; Lollini PL; Colombo MP; Forni G
    J Exp Med; 1998 Aug; 188(3):589-96. PubMed ID: 9687535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA.
    Sfondrini L; Besusso D; Rumio C; Rodolfo M; Ménard S; Balsari A
    FASEB J; 2002 Nov; 16(13):1749-54. PubMed ID: 12409317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.
    Rovero S; Boggio K; Di Carlo E; Amici A; Quaglino E; Porcedda P; Musiani P; Forni G
    Gene Ther; 2001 Mar; 8(6):447-52. PubMed ID: 11313823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
    Sharma S; Dominguez AL; Manrique SZ; Cavallo F; Sakaguchi S; Lustgarten J
    Cancer Res; 2008 Sep; 68(18):7530-40. PubMed ID: 18794141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.
    Lo Iacono M; Cavallo F; Quaglino E; Rolla S; Iezzi M; Pupa SM; De Giovanni C; Lollini PL; Musiani P; Forni G; Calogero RA
    Int J Immunopathol Pharmacol; 2005; 18(2):351-63. PubMed ID: 15888257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
    Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
    Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone promotes immunomodulation and tumor development in the murine mammary gland.
    Werner LR; Gibson KA; Goodman ML; Helm DE; Walter KR; Holloran SM; Trinca GM; Hastings RC; Yang HH; Hu Y; Wei J; Lei G; Yang XY; Madan R; Molinolo AA; Markiewicz MA; Chalise P; Axelrod ML; Balko JM; Hunter KW; Hartman ZC; Lange CA; Hagan CR
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33958486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice.
    Curcio C; Khan AS; Amici A; Spadaro M; Quaglino E; Cavallo F; Forni G; Draghia-Akli R
    Cancer Gene Ther; 2008 Feb; 15(2):108-14. PubMed ID: 17992201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.